Clin2
NCT07100119Possibly a fitRecruiting

Study of LY4256984 for people with sporadic ALS

ALS (Amyotrophic Lateral Sclerosis)

Treatments studied

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests a new medicine called LY4256984 for people with sporadic ALS (ALS not caused by a known genetic mutation). The goal is to see if the drug is safe and how it affects the body. It may offer a new treatment option for people recently diagnosed with ALS.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
32 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have a diagnosis of sporadic ALS (not the inherited kind) confirmed by a doctor.
  • Your ALS symptoms must have started within the last 2 years.
  • Your body mass index (BMI) must be between 18.0 and 35.0 (inclusive).
  • You cannot have other serious medical conditions or a history of other neurodegenerative diseases.
  • Your liver and kidney function must be within normal limits, and you must not have significant abnormalities on a heart test or spine X-ray.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07082192Not yet recruiting· Phase 2/Phase 3
Testing CB03-154 for adults with ALS

This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.

NCT07400393Not yet recruiting
ALS genetic matching study

This study aims to match people with ALS to potential treatments based on their genetic profile. It connects you to a network of trials that may be relevant to your specific type of ALS.

NCT07571200Recruiting· Phase 1
Study of LY4256984 for ALS in Previous Trial Participants

This is a follow-up study for people with ALS who have already completed another Eli Lilly ALS treatment trial. Researchers want to continue testing a new drug (LY4256984) in people who tolerated the previous treatment well.

Leuven
NCT07571174Recruiting· Phase 1
ALS Study: Testing a New Drug in Spinal Fluid

This is a follow-up study for people with ALS (a disease affecting nerve and muscle control) who completed a previous trial called OWAA. Researchers want to test how a new experimental drug called LY4256984 affects the spinal fluid around your brain and spine, which may help them understand if it could slow disease progression.

Leuven
NCT07660614Recruiting· Phase 1/Phase 2
Testing a new drug for people with ALS

This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.

Lübeck
NCT06513546Not yet recruiting· Phase 1/Phase 2
Testing a new drug (PLL001) for early-stage ALS

This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.

Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.